Vinehealth, an application to support quality of life and outcomes of cancer patients, has raised £4.1 million in its latest funding round, led by Talis Capital.
The app provides the functionality for patients to digitally track their symptoms and side effects, with an aim to help them manage their care and improve communication with carers.
The company said the tool also supports pharmaceutical companies to deliver ‘scalable patient support programmes’ and collect ‘patient-reported outcomes data to support clinical trials and studies’. Vinehealth noted it has “already secured its position as the preferred supplier to six top 10 global pharmaceutical companies”.
Rayna Patel, founder and CEO of Vinehealth, commented on the funding raise: “We are delighted to have received such credible investor support to continue on our mission to empower and support those with cancer.
“It’s imperative that we start understanding how therapies are affecting patients: for pharmaceutical companies, our technology enables deeper patient understanding which leads to better drugs, greater differentiation and faster licensing, as well as the ability to provide personalised scalable support to patients. For patients, this means better care and improved outcomes from cancer. We’re now looking forward to applying our rich data and machine learning capabilities to novel predictive analytics to generate even richer insights for our life science partners.”
The company now plans to use the funding to further develop its product, scale its team and expand in the US.
Details on the investors were published, which include Playfair Capital and Ascension. A number of angels also participated, including Keith Gibbs, former CEO of AXA PPP Healthcare; Pam Garside, partner at Newhealth; VOYAGERS Health-Tech Fund, led by David Rowan, founding editor of WIRED; David Giampaolo, healthcare entrepreneur and founder of PI Capital; Deepali Nangia, venture partner at Speedinvest and Atomico Angel; Faisal Mehmud, Vice President and former Medical Director of Bristol Myers Squibb; and KHP MedTech Innovations, a collaboration between King’s College London, King’s College Hospital NHS Foundation Trust and Guy’s and St Thomas’ NHS Trust.